8-K: Applied Therapeutics Announces Positive Interim Results for SORD Deficiency Drug

Applied Therapeutics reports positive 12-month interim results from its Phase 3 INSPIRE trial for govorestat, a potential treatment for SORD Deficiency.

Summary

• Applied Therapeutics announced positive interim 12-month results from the Phase 3 INSPIRE trial for govorestat (AT-007), a drug being developed to treat SORD Deficiency.
• The trial included 56 patients aged 16-55 with SORD Deficiency in the US and Europe.
• SORD Deficiency is a hereditary condition that causes motor neuron degeneration and loss of mobility due to the accumulation of sorbitol.
• The interim analysis showed a statistically significant correlation between sorbitol levels and clinical outcomes (p=0.05).
• Govorestat treatment resulted in a statistically significant reduction in sorbitol levels compared to placebo (p<0.001).
• The treatment also showed a highly statistically significant effect on the CMT Health Index (CMT-HI) (p=0.01), a measure of disease severity and well-being.
• Govorestat was found to be safe and well-tolerated, with similar adverse event rates in both the treatment and placebo groups.
• The company plans to discuss a potential New Drug Application (NDA) submission with the FDA based on the data.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with statistically significant improvements and a clear path towards regulatory approval. The lack of negative information and the focus on future steps contribute to a high sentiment score.

Positives

• The study met its primary endpoints, demonstrating the effectiveness of govorestat in reducing sorbitol levels.
• The drug showed a significant positive impact on patient-reported outcomes, such as mobility and fatigue.
• The safety profile of govorestat was favorable, with no significant differences in adverse events compared to placebo.
• The results support the role of sorbitol as a key driver of disease severity and progression in SORD Deficiency.
• The company is moving forward with plans to discuss a potential NDA submission with the FDA.

Risks

• The company's plans to develop, market, and commercialize product candidates are subject to risks.
• The initiation, timing, progress, and results of clinical trials are uncertain.
• The company's ability to obtain regulatory approval for its product candidates is not guaranteed.
• There are risks associated with the company's ability to secure additional funding.
• The company faces competition in the markets it serves.

Future Outlook

The company plans to discuss a potential New Drug Application (NDA) submission with the FDA based on the clinical data to date. Clinical outcomes of the ongoing INSPIRE trial are expected to be assessed again at 24 months.

Management Comments

• We believe the results from the 12-month interim analysis confirm the role of sorbitol as a key driver of disease severity and progression over time.

Industry Context

This announcement is significant as there are currently no approved treatments for SORD Deficiency, a rare and debilitating disease. The positive results from the INSPIRE trial could position Applied Therapeutics as a leader in this therapeutic area.

Comparison to Industry Standards

• The results are promising compared to the lack of existing treatments for SORD Deficiency.
• The statistically significant reduction in sorbitol levels and improvement in the CMT-HI are strong indicators of potential efficacy.
• The safety profile of govorestat appears to be favorable, which is important for a chronic treatment.

Stakeholder Impact

• Shareholders will likely react positively to the positive clinical trial results.
• Patients with SORD Deficiency and their families may have renewed hope for a treatment option.
• The company's employees may be motivated by the progress of the drug development program.

Next Steps

• The company plans to discuss a potential NDA submission with the FDA.
• Clinical outcomes of the ongoing INSPIRE trial are expected to be assessed again at 24 months.

Key Dates

Keywords

SORD Deficiency, Govorestat, AT-007, Phase 3 Trial, Clinical Trial, Neuropathy, Aldose Reductase Inhibitor, FDA, NDA, Sorbitol